Current Context: CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB) and TATA Sons signed a MoU for licensing of KNOWHOW for FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) for rapid diagnosis of COVID-19.
- The MoU is signed to receive the license which includes the transfer of the knowledge for scaling up the KNOWHOW in the form of a kit that can be deployed for COVID-19 testing on ground in May 2020.
- FELUDA is a complete indigenous scientific invention that has been designed to mitigate the ongoing COVID-19 situation. It is highly affordable, relatively easy to use, and non-dependent on expensive Q-PCR machines.
- This innovative CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) ‘Feluda’ test uses cutting edge CRISPR technology for detection of genomic sequence of novel coronavirus.
- CSIR IGIB and TATA Sons will work together to bring FELUDA for widespread use at the earliest.
Question:
Q.1 With whom CSIR-IGIB has signed MoU to license KNOWHOW for FELUDA?
a. Aditya Birla Group
b. Reliance Industries
c. TATA Sons
d. Essar
a. Aditya Birla Group
b. Reliance Industries
c. TATA Sons
d. Essar
